aluates Reports

$ 0.0

Automative

Global Idiopathic Pulmonary Fibrosis Market Research Report 2025

Published Date: September 2025

Report Code: QYRE-Auto-8O6240

Global Idiopathic Pulmonary Fibrosis Market Size Status and Forecast 2021 2027

BUY CHAPTERS

Global Idiopathic Pulmonary Fibrosis Market Research Report 2025

Code: QYRE-Auto-8O6240

Report

September 2025

Pages:77

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Medicinova, Inc.

Boehringer Ingelheim

F.Hoffmann-La Roche

FibroGen Inc

Promedior Inc

Merck

Galapagos

ProMetic Life Sciences

Cipla Ltd

Idiopathic Pulmonary Fibrosis Market Size

The global market for Idiopathic Pulmonary Fibrosis was valued at US$ 2124 million in the year 2024 and is projected to reach a revised size of US$ 3975 million by 2031, growing at a CAGR of 9.5% during the forecast period.

Idiopathic Pulmonary Fibrosis Market

Idiopathic pulmonary fibrosis is a condition in which the tissues in the lungs become thick and stiff over time. As a result of thickening of lung tissues, brain and other organs are unable receive optimum oxygen.

An increase in the incidence and prevalence of fibrotic diseases is the primary driver for the growth of this market. Idiopathic pulmonary fibrosis most commonly affects middle-aged to older adults and is characterized by the scarring of lung tissues. In older people, these scars tend to build up and affect the normal functioning of lungs. Thus, an increase in aging population leads to increased prevalence of the disease, which in turn results in market growth during the predicted period.

This report aims to provide a comprehensive presentation of the global market for Idiopathic Pulmonary Fibrosis, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Idiopathic Pulmonary Fibrosis.

The Idiopathic Pulmonary Fibrosis market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Idiopathic Pulmonary Fibrosis market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Idiopathic Pulmonary Fibrosis companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Idiopathic Pulmonary Fibrosis Market Report

Report Metric	Details
Report Name	Idiopathic Pulmonary Fibrosis Market
Accounted market size in year	US$ 2124 million
Forecasted market size in 2031	US$ 3975 million
CAGR	9.5%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Systemic Corticosteroids Immunosuppressant Drugs Tyrosine Kinase Inhibitors Antifibrotic Agents
Segment by Application	Hospitals Clinics Ambulatory Surgical Centers Academic and Research Organizations
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	MediciNova, Boehringer Ingelheim, F. Hoffmann-La Roche, FibroGen, Promedior, Merck, Galapagos, Prometic Life Sciences, Cipla
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Idiopathic Pulmonary Fibrosis company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Idiopathic Pulmonary Fibrosis Market growing?

Ans: The Idiopathic Pulmonary Fibrosis Market witnessing a CAGR of 9.5% during the forecast period 2025-2031.

What is the Idiopathic Pulmonary Fibrosis Market size in 2031?

Ans: The Idiopathic Pulmonary Fibrosis Market size in 2031 will be US$ 3975 million.

Who are the main players in the Idiopathic Pulmonary Fibrosis Market report?

Ans: The main players in the Idiopathic Pulmonary Fibrosis Market are MediciNova, Boehringer Ingelheim, F. Hoffmann-La Roche, FibroGen, Promedior, Merck, Galapagos, Prometic Life Sciences, Cipla

What are the Application segmentation covered in the Idiopathic Pulmonary Fibrosis Market report?

Ans: The Applications covered in the Idiopathic Pulmonary Fibrosis Market report are Hospitals, Clinics, Ambulatory Surgical Centers, Academic and Research Organizations

What are the Type segmentation covered in the Idiopathic Pulmonary Fibrosis Market report?

Ans: The Types covered in the Idiopathic Pulmonary Fibrosis Market report are Systemic Corticosteroids, Immunosuppressant Drugs, Tyrosine Kinase Inhibitors, Antifibrotic Agents

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Idiopathic Pulmonary Fibrosis Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Systemic Corticosteroids

1.2.3 Immunosuppressant Drugs

1.2.4 Tyrosine Kinase Inhibitors

1.2.5 Antifibrotic Agents

1.3 Market by Application

1.3.1 Global Idiopathic Pulmonary Fibrosis Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Hospitals

1.3.3 Clinics

1.3.4 Ambulatory Surgical Centers

1.3.5 Academic and Research Organizations

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Idiopathic Pulmonary Fibrosis Market Perspective (2020-2031)

2.2 Global Idiopathic Pulmonary Fibrosis Growth Trends by Region

2.2.1 Global Idiopathic Pulmonary Fibrosis Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Idiopathic Pulmonary Fibrosis Historic Market Size by Region (2020-2025)

2.2.3 Idiopathic Pulmonary Fibrosis Forecasted Market Size by Region (2026-2031)

2.3 Idiopathic Pulmonary Fibrosis Market Dynamics

2.3.1 Idiopathic Pulmonary Fibrosis Industry Trends

2.3.2 Idiopathic Pulmonary Fibrosis Market Drivers

2.3.3 Idiopathic Pulmonary Fibrosis Market Challenges

2.3.4 Idiopathic Pulmonary Fibrosis Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Idiopathic Pulmonary Fibrosis Players by Revenue

3.1.1 Global Top Idiopathic Pulmonary Fibrosis Players by Revenue (2020-2025)

3.1.2 Global Idiopathic Pulmonary Fibrosis Revenue Market Share by Players (2020-2025)

3.2 Global Idiopathic Pulmonary Fibrosis Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Idiopathic Pulmonary Fibrosis Revenue

3.4 Global Idiopathic Pulmonary Fibrosis Market Concentration Ratio

3.4.1 Global Idiopathic Pulmonary Fibrosis Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Idiopathic Pulmonary Fibrosis Revenue in 2024

3.5 Global Key Players of Idiopathic Pulmonary Fibrosis Head office and Area Served

3.6 Global Key Players of Idiopathic Pulmonary Fibrosis, Product and Application

3.7 Global Key Players of Idiopathic Pulmonary Fibrosis, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Idiopathic Pulmonary Fibrosis Breakdown Data by Type

4.1 Global Idiopathic Pulmonary Fibrosis Historic Market Size by Type (2020-2025)

4.2 Global Idiopathic Pulmonary Fibrosis Forecasted Market Size by Type (2026-2031)

5 Idiopathic Pulmonary Fibrosis Breakdown Data by Application

5.1 Global Idiopathic Pulmonary Fibrosis Historic Market Size by Application (2020-2025)

5.2 Global Idiopathic Pulmonary Fibrosis Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Idiopathic Pulmonary Fibrosis Market Size (2020-2031)

6.2 North America Idiopathic Pulmonary Fibrosis Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Idiopathic Pulmonary Fibrosis Market Size by Country (2020-2025)

6.4 North America Idiopathic Pulmonary Fibrosis Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Idiopathic Pulmonary Fibrosis Market Size (2020-2031)

7.2 Europe Idiopathic Pulmonary Fibrosis Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Idiopathic Pulmonary Fibrosis Market Size by Country (2020-2025)

7.4 Europe Idiopathic Pulmonary Fibrosis Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size (2020-2031)

8.2 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size by Region (2020-2025)

8.4 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Idiopathic Pulmonary Fibrosis Market Size (2020-2031)

9.2 Latin America Idiopathic Pulmonary Fibrosis Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Idiopathic Pulmonary Fibrosis Market Size by Country (2020-2025)

9.4 Latin America Idiopathic Pulmonary Fibrosis Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Idiopathic Pulmonary Fibrosis Market Size (2020-2031)

10.2 Middle East & Africa Idiopathic Pulmonary Fibrosis Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Idiopathic Pulmonary Fibrosis Market Size by Country (2020-2025)

10.4 Middle East & Africa Idiopathic Pulmonary Fibrosis Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 MediciNova

11.1.1 MediciNova Company Details

11.1.2 MediciNova Business Overview

11.1.3 MediciNova Idiopathic Pulmonary Fibrosis Introduction

11.1.4 MediciNova Revenue in Idiopathic Pulmonary Fibrosis Business (2020-2025)

11.1.5 MediciNova Recent Development

11.2 Boehringer Ingelheim

11.2.1 Boehringer Ingelheim Company Details

11.2.2 Boehringer Ingelheim Business Overview

11.2.3 Boehringer Ingelheim Idiopathic Pulmonary Fibrosis Introduction

11.2.4 Boehringer Ingelheim Revenue in Idiopathic Pulmonary Fibrosis Business (2020-2025)

11.2.5 Boehringer Ingelheim Recent Development

11.3 F. Hoffmann-La Roche

11.3.1 F. Hoffmann-La Roche Company Details

11.3.2 F. Hoffmann-La Roche Business Overview

11.3.3 F. Hoffmann-La Roche Idiopathic Pulmonary Fibrosis Introduction

11.3.4 F. Hoffmann-La Roche Revenue in Idiopathic Pulmonary Fibrosis Business (2020-2025)

11.3.5 F. Hoffmann-La Roche Recent Development

11.4 FibroGen

11.4.1 FibroGen Company Details

11.4.2 FibroGen Business Overview

11.4.3 FibroGen Idiopathic Pulmonary Fibrosis Introduction

11.4.4 FibroGen Revenue in Idiopathic Pulmonary Fibrosis Business (2020-2025)

11.4.5 FibroGen Recent Development

11.5 Promedior

11.5.1 Promedior Company Details

11.5.2 Promedior Business Overview

11.5.3 Promedior Idiopathic Pulmonary Fibrosis Introduction

11.5.4 Promedior Revenue in Idiopathic Pulmonary Fibrosis Business (2020-2025)

11.5.5 Promedior Recent Development

11.6 Merck

11.6.1 Merck Company Details

11.6.2 Merck Business Overview

11.6.3 Merck Idiopathic Pulmonary Fibrosis Introduction

11.6.4 Merck Revenue in Idiopathic Pulmonary Fibrosis Business (2020-2025)

11.6.5 Merck Recent Development

11.7 Galapagos

11.7.1 Galapagos Company Details

11.7.2 Galapagos Business Overview

11.7.3 Galapagos Idiopathic Pulmonary Fibrosis Introduction

11.7.4 Galapagos Revenue in Idiopathic Pulmonary Fibrosis Business (2020-2025)

11.7.5 Galapagos Recent Development

11.8 Prometic Life Sciences

11.8.1 Prometic Life Sciences Company Details

11.8.2 Prometic Life Sciences Business Overview

11.8.3 Prometic Life Sciences Idiopathic Pulmonary Fibrosis Introduction

11.8.4 Prometic Life Sciences Revenue in Idiopathic Pulmonary Fibrosis Business (2020-2025)

11.8.5 Prometic Life Sciences Recent Development

11.9 Cipla

11.9.1 Cipla Company Details

11.9.2 Cipla Business Overview

11.9.3 Cipla Idiopathic Pulmonary Fibrosis Introduction

11.9.4 Cipla Revenue in Idiopathic Pulmonary Fibrosis Business (2020-2025)

11.9.5 Cipla Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Medicinova, Inc.

Boehringer Ingelheim

F.Hoffmann-La Roche

FibroGen Inc

Promedior Inc

Merck

Galapagos

ProMetic Life Sciences

Cipla Ltd

List of Tables

Table 1. Global Idiopathic Pulmonary Fibrosis Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Systemic Corticosteroids

Table 3. Key Players of Immunosuppressant Drugs

Table 4. Key Players of Tyrosine Kinase Inhibitors

Table 5. Key Players of Antifibrotic Agents

Table 6. Global Idiopathic Pulmonary Fibrosis Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 7. Global Idiopathic Pulmonary Fibrosis Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 8. Global Idiopathic Pulmonary Fibrosis Market Size by Region (2020-2025) & (US$ Million)

Table 9. Global Idiopathic Pulmonary Fibrosis Market Share by Region (2020-2025)

Table 10. Global Idiopathic Pulmonary Fibrosis Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 11. Global Idiopathic Pulmonary Fibrosis Market Share by Region (2026-2031)

Table 12. Idiopathic Pulmonary Fibrosis Market Trends

Table 13. Idiopathic Pulmonary Fibrosis Market Drivers

Table 14. Idiopathic Pulmonary Fibrosis Market Challenges

Table 15. Idiopathic Pulmonary Fibrosis Market Restraints

Table 16. Global Idiopathic Pulmonary Fibrosis Revenue by Players (2020-2025) & (US$ Million)

Table 17. Global Idiopathic Pulmonary Fibrosis Market Share by Players (2020-2025)

Table 18. Global Top Idiopathic Pulmonary Fibrosis Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Idiopathic Pulmonary Fibrosis as of 2024)

Table 19. Ranking of Global Top Idiopathic Pulmonary Fibrosis Companies by Revenue (US$ Million) in 2024

Table 20. Global 5 Largest Players Market Share by Idiopathic Pulmonary Fibrosis Revenue (CR5 and HHI) & (2020-2025)

Table 21. Global Key Players of Idiopathic Pulmonary Fibrosis, Headquarters and Area Served

Table 22. Global Key Players of Idiopathic Pulmonary Fibrosis, Product and Application

Table 23. Global Key Players of Idiopathic Pulmonary Fibrosis, Date of Enter into This Industry

Table 24. Mergers & Acquisitions, Expansion Plans

Table 25. Global Idiopathic Pulmonary Fibrosis Market Size by Type (2020-2025) & (US$ Million)

Table 26. Global Idiopathic Pulmonary Fibrosis Revenue Market Share by Type (2020-2025)

Table 27. Global Idiopathic Pulmonary Fibrosis Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 28. Global Idiopathic Pulmonary Fibrosis Revenue Market Share by Type (2026-2031)

Table 29. Global Idiopathic Pulmonary Fibrosis Market Size by Application (2020-2025) & (US$ Million)

Table 30. Global Idiopathic Pulmonary Fibrosis Revenue Market Share by Application (2020-2025)

Table 31. Global Idiopathic Pulmonary Fibrosis Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 32. Global Idiopathic Pulmonary Fibrosis Revenue Market Share by Application (2026-2031)

Table 33. North America Idiopathic Pulmonary Fibrosis Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 34. North America Idiopathic Pulmonary Fibrosis Market Size by Country (2020-2025) & (US$ Million)

Table 35. North America Idiopathic Pulmonary Fibrosis Market Size by Country (2026-2031) & (US$ Million)

Table 36. Europe Idiopathic Pulmonary Fibrosis Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 37. Europe Idiopathic Pulmonary Fibrosis Market Size by Country (2020-2025) & (US$ Million)

Table 38. Europe Idiopathic Pulmonary Fibrosis Market Size by Country (2026-2031) & (US$ Million)

Table 39. Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 40. Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size by Region (2020-2025) & (US$ Million)

Table 41. Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size by Region (2026-2031) & (US$ Million)

Table 42. Latin America Idiopathic Pulmonary Fibrosis Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 43. Latin America Idiopathic Pulmonary Fibrosis Market Size by Country (2020-2025) & (US$ Million)

Table 44. Latin America Idiopathic Pulmonary Fibrosis Market Size by Country (2026-2031) & (US$ Million)

Table 45. Middle East & Africa Idiopathic Pulmonary Fibrosis Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 46. Middle East & Africa Idiopathic Pulmonary Fibrosis Market Size by Country (2020-2025) & (US$ Million)

Table 47. Middle East & Africa Idiopathic Pulmonary Fibrosis Market Size by Country (2026-2031) & (US$ Million)

Table 48. MediciNova Company Details

Table 49. MediciNova Business Overview

Table 50. MediciNova Idiopathic Pulmonary Fibrosis Product

Table 51. MediciNova Revenue in Idiopathic Pulmonary Fibrosis Business (2020-2025) & (US$ Million)

Table 52. MediciNova Recent Development

Table 53. Boehringer Ingelheim Company Details

Table 54. Boehringer Ingelheim Business Overview

Table 55. Boehringer Ingelheim Idiopathic Pulmonary Fibrosis Product

Table 56. Boehringer Ingelheim Revenue in Idiopathic Pulmonary Fibrosis Business (2020-2025) & (US$ Million)

Table 57. Boehringer Ingelheim Recent Development

Table 58. F. Hoffmann-La Roche Company Details

Table 59. F. Hoffmann-La Roche Business Overview

Table 60. F. Hoffmann-La Roche Idiopathic Pulmonary Fibrosis Product

Table 61. F. Hoffmann-La Roche Revenue in Idiopathic Pulmonary Fibrosis Business (2020-2025) & (US$ Million)

Table 62. F. Hoffmann-La Roche Recent Development

Table 63. FibroGen Company Details

Table 64. FibroGen Business Overview

Table 65. FibroGen Idiopathic Pulmonary Fibrosis Product

Table 66. FibroGen Revenue in Idiopathic Pulmonary Fibrosis Business (2020-2025) & (US$ Million)

Table 67. FibroGen Recent Development

Table 68. Promedior Company Details

Table 69. Promedior Business Overview

Table 70. Promedior Idiopathic Pulmonary Fibrosis Product

Table 71. Promedior Revenue in Idiopathic Pulmonary Fibrosis Business (2020-2025) & (US$ Million)

Table 72. Promedior Recent Development

Table 73. Merck Company Details

Table 74. Merck Business Overview

Table 75. Merck Idiopathic Pulmonary Fibrosis Product

Table 76. Merck Revenue in Idiopathic Pulmonary Fibrosis Business (2020-2025) & (US$ Million)

Table 77. Merck Recent Development

Table 78. Galapagos Company Details

Table 79. Galapagos Business Overview

Table 80. Galapagos Idiopathic Pulmonary Fibrosis Product

Table 81. Galapagos Revenue in Idiopathic Pulmonary Fibrosis Business (2020-2025) & (US$ Million)

Table 82. Galapagos Recent Development

Table 83. Prometic Life Sciences Company Details

Table 84. Prometic Life Sciences Business Overview

Table 85. Prometic Life Sciences Idiopathic Pulmonary Fibrosis Product

Table 86. Prometic Life Sciences Revenue in Idiopathic Pulmonary Fibrosis Business (2020-2025) & (US$ Million)

Table 87. Prometic Life Sciences Recent Development

Table 88. Cipla Company Details

Table 89. Cipla Business Overview

Table 90. Cipla Idiopathic Pulmonary Fibrosis Product

Table 91. Cipla Revenue in Idiopathic Pulmonary Fibrosis Business (2020-2025) & (US$ Million)

Table 92. Cipla Recent Development

Table 93. Research Programs/Design for This Report

Table 94. Key Data Information from Secondary Sources

Table 95. Key Data Information from Primary Sources

Table 96. Authors List of This Report

List of Figures

Figure 1. Idiopathic Pulmonary Fibrosis Picture

Figure 2. Global Idiopathic Pulmonary Fibrosis Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Idiopathic Pulmonary Fibrosis Market Share by Type: 2024 VS 2031

Figure 4. Systemic Corticosteroids Features

Figure 5. Immunosuppressant Drugs Features

Figure 6. Tyrosine Kinase Inhibitors Features

Figure 7. Antifibrotic Agents Features

Figure 8. Global Idiopathic Pulmonary Fibrosis Market Size by Application (2020-2031) & (US$ Million)

Figure 9. Global Idiopathic Pulmonary Fibrosis Market Share by Application: 2024 VS 2031

Figure 10. Hospitals Case Studies

Figure 11. Clinics Case Studies

Figure 12. Ambulatory Surgical Centers Case Studies

Figure 13. Academic and Research Organizations Case Studies

Figure 14. Idiopathic Pulmonary Fibrosis Report Years Considered

Figure 15. Global Idiopathic Pulmonary Fibrosis Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 16. Global Idiopathic Pulmonary Fibrosis Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 17. Global Idiopathic Pulmonary Fibrosis Market Share by Region: 2024 VS 2031

Figure 18. Global Idiopathic Pulmonary Fibrosis Market Share by Players in 2024

Figure 19. Global Top Idiopathic Pulmonary Fibrosis Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Idiopathic Pulmonary Fibrosis as of 2024)

Figure 20. The Top 10 and 5 Players Market Share by Idiopathic Pulmonary Fibrosis Revenue in 2024

Figure 21. North America Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 22. North America Idiopathic Pulmonary Fibrosis Market Share by Country (2020-2031)

Figure 23. United States Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. Canada Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. Europe Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. Europe Idiopathic Pulmonary Fibrosis Market Share by Country (2020-2031)

Figure 27. Germany Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. France Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. U.K. Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Italy Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Russia Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Nordic Countries Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. Asia-Pacific Idiopathic Pulmonary Fibrosis Market Share by Region (2020-2031)

Figure 35. China Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. Japan Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. South Korea Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Southeast Asia Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. India Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Australia Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Latin America Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Latin America Idiopathic Pulmonary Fibrosis Market Share by Country (2020-2031)

Figure 43. Mexico Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Brazil Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Middle East & Africa Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. Middle East & Africa Idiopathic Pulmonary Fibrosis Market Share by Country (2020-2031)

Figure 47. Turkey Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. Saudi Arabia Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 49. UAE Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 50. MediciNova Revenue Growth Rate in Idiopathic Pulmonary Fibrosis Business (2020-2025)

Figure 51. Boehringer Ingelheim Revenue Growth Rate in Idiopathic Pulmonary Fibrosis Business (2020-2025)

Figure 52. F. Hoffmann-La Roche Revenue Growth Rate in Idiopathic Pulmonary Fibrosis Business (2020-2025)

Figure 53. FibroGen Revenue Growth Rate in Idiopathic Pulmonary Fibrosis Business (2020-2025)

Figure 54. Promedior Revenue Growth Rate in Idiopathic Pulmonary Fibrosis Business (2020-2025)

Figure 55. Merck Revenue Growth Rate in Idiopathic Pulmonary Fibrosis Business (2020-2025)

Figure 56. Galapagos Revenue Growth Rate in Idiopathic Pulmonary Fibrosis Business (2020-2025)

Figure 57. Prometic Life Sciences Revenue Growth Rate in Idiopathic Pulmonary Fibrosis Business (2020-2025)

Figure 58. Cipla Revenue Growth Rate in Idiopathic Pulmonary Fibrosis Business (2020-2025)

Figure 59. Bottom-up and Top-down Approaches for This Report

Figure 60. Data Triangulation

Figure 61. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

120 Pages

Type: Report

Code: QYRE-Auto-29F16707

Wed Nov 12 00:00:00 UTC 2025

Add to Cart

Global Asthma Attack Alert System Market Outlook, In‑Depth Analysis & Forecast to 2031

120 Pages

Type: Report

Code: QYRE-Auto-19R17068

Wed Nov 12 00:00:00 UTC 2025

Add to Cart

Global Heated Humidified High-Flow Therapy Systems Market Outlook, In‑Depth Analysis & Forecast to 2031

120 Pages

Type: Report

Code: QYRE-Auto-20V17068

Tue Nov 11 00:00:00 UTC 2025

Add to Cart

Global Computer-based Spirometer Market Outlook, In‑Depth Analysis & Forecast to 2031

120 Pages

Type: Report

Code: QYRE-Auto-36W16800

Mon Nov 10 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions

Global Idiopathic Pulmonary Fibrosis Market Research Report 2025

Published Date: September 2025

Report Code: QYRE-Auto-8O6240

Global Idiopathic Pulmonary Fibrosis Market Research Report 2025

FEATURED COMPANIES

Idiopathic Pulmonary Fibrosis Market Size

Idiopathic Pulmonary Fibrosis Market

Scope of Idiopathic Pulmonary Fibrosis Market Report

Chapter Outline

FAQ for this report

How fast is Idiopathic Pulmonary Fibrosis Market growing?

What is the Idiopathic Pulmonary Fibrosis Market size in 2031?

Who are the main players in the Idiopathic Pulmonary Fibrosis Market report?

What are the Application segmentation covered in the Idiopathic Pulmonary Fibrosis Market report?

What are the Type segmentation covered in the Idiopathic Pulmonary Fibrosis Market report?

FEATURED COMPANIES

RELATED REPORTS